Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03948854 · ClinicalTrials.gov registry record · NA
Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT03948854: Completed NA study, sponsored by Mayo Clinic.
NCT03948854 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03948854, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
Researchers are trying to determine the best course of action regarding the dietary management with a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP diet) for irritable bowel syndrome.
Primary Outcome
Change in IBS symptoms will be measured from baseline to the end of study using the validated IBS symptoms severity scale (IBS-SS). This is a visual analog scale from 0-100. The primary outcome measure is improvement in symptom scores from end of study to baseline.
Interventions
- OTHER Registered dietitian
- OTHER On-line video program
- OTHER Printed handout
- OTHER Dietitian-led group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2022-02-19 |
| Phase | NA |
What the finished NCT03948854 record still lists
NCT03948854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Registered dietitian is the first listed.
NCT03948854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03948854 about?
NCT03948854 is a clinical study titled "Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients". Researchers are trying to determine the best course of action regarding the dietary management with a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP diet) for irritable bowel syndrome.
What is the current status of trial NCT03948854?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2019-05-22. Estimated completion is 2022-02-19.
What interventions are being tested in trial NCT03948854?
The interventions under investigation include: Registered dietitian (OTHER), On-line video program (OTHER), Printed handout (OTHER), Dietitian-led group (OTHER).
Who is sponsoring clinical trial NCT03948854?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03948854's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI